Get ready for a game-changer in the world of CRISPR medicine! nChroma Bio has just cleared a major hurdle in their quest to develop a revolutionary treatment for hepatitis B.
In a groundbreaking move, nChroma Bio has received the green light from Hong Kong's regulatory authorities to initiate a Phase 1/2 clinical trial for their lead candidate, CRMA-1001. This marks a significant milestone not only for the company but also for the entire field of hepatitis B research and treatment.
By: Gorm Palmgren - Dec. 17, 2025
The decision to move forward with this clinical trial is especially notable because it focuses on a finite-course, functional cure strategy rather than the traditional lifelong viral suppression approach. It's a bold step towards a potential paradigm shift in hepatitis B treatment.
"This regulatory clearance is a defining moment for nChroma and for those affected by chronic HBV," says Jeff Walsh, CEO of nChroma Bio. "We're excited to explore the potential of our epigenetic silencing platform and its ability to offer a more sustainable solution."
